|
|
The effect of silenced focal adhesion kinase on colorectal cancer metastasis in vivo |
1.Department of General Surgery, the First People’s Hospital of Taizhou, Taizhou, 318020; 2.Department of General Surgery, the First Affiliated Hospital of Xiamen University, Xiamen, 361000; 3.Special Service Ward, the First People’s Hospital of Taizhou, Taizhou, 318020 |
|
Cite this article: |
HONG Weiwen1,SU Guoqiang2,YING Hongan3, et al. The effect of silenced focal adhesion kinase on colorectal cancer metastasis in vivo[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(7): 497-.
|
|
Abstract Objective: Focal adhesion kinase gene silencing by Short Hairpin RNA can effectively inhibit colorectal cancer’s metastasis were confirmed through injection of FAK-knockdown colorectal cancer cells into nude mice. Methods: Twenty-four nude mice were randomly divided into three groups which were experimental group which inject FAK-knockdown colon cancer cells, negative control group whick inject negative control colon cancer cells and untreated group which inject untreated colon cancer cells. Nude mice were sacrificed after 6 weeks and tumor formation rate, mortality, tumor growth, liver and lung’s metastasis, miscrometastasis were observed and FAK protein expression were determined with HE staining and immunohistochemical staining. Results: Tumor formation rate was 100% in each group. Distant metastases, mortality and FAK protein expression of experimental group was significantly lower than that of the other two groups (P<0.05), meanwhile, the malignant lesion extent was lighter. While negative control group and untreated group were not significantly different (P>0.05). Conclusion: Lentiviral packaging shRNA-mediated FAK gene silencing can significantly inhibit liver and lung metastasis of colorectal cancer. FAK is expected to be a new target for treatment of colon cancer metastasis.
|
Received: 18 February 2014
|
|
|
|
|
[1] Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006[J]. Ann Oncol, 2007, 18(6): 581-592.
[2] Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2009, 59(4): 225-249.
[3] Saletti P, Cavalli F. Metastatic colorectal cancer[J]. Cancer Treat Rev, 2006, 32(7): 557-571.
[4] Tol Jolien, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review[J]. Clinical Therapeutics, 2010, 32(3): 437-453.
[5] 洪卫文, 苏国强, 应红安, 等. 稳定沉默黏着斑激酶结肠癌细胞株SW620的建立[J]. 温州医科大学学报, 2014, 44 (3): 201-204.
[6] 倪孔海, 翁志梁, 王思齐, 等. 粘着斑激酶在人良性前列腺增生组织中的表达及其意义[J]. 温州医学院学报, 2004, 34(4): 262-264.
[7] Seo CH, Jeong H, Feng Y, et al. Micropit surfaces designed for accelerating osteogenic differentiation of murine mesenchymal stem cells via enhancing focal adhesion and actin polymerization[J]. Biomaterials, 2013, 12(35): 2245-2252.
[8] 孙晓杰, 黄常志. PI3K-Akt信号通路与肿瘤[J]. 世界华人消化杂志, 2006, 14(3): 306-311.
[9] Yu HG, Tong SL, Ding YM, et al. Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase[J]. Int J Cancer, 2006, 119(12): 2724-2732.
[10] Stoeck A, Gast D, Sanderson MP, et al. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells[J]. Gynecol Oncol, 2007, 104(2): 461-469.
[11] Serrels A, Canel M, Brunton VG, et al. Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging[J].Cell Adh Migr, 2011, 5: 360-365.
[12] 袁周, 郑起, 黄新余, 等. 抑制黏着斑激酶表达对人肝癌细胞转移潜能的作用[J]. 中华外科杂志, 2007, 45(19): 1350-1353.
[13] Figel S, Gelman I. Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions[J]. Anticancer Agents Med Chem, 2011, 11(7): 607-616.
[14] Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies[J]. Br J Surg, 2006, 94 (7): 982-999.
[15] Iwasaki A, Shirakusa T, Yamashita Y, et al. Characteristic differences between patients who have undergone surgical treatment for lung metastasis or hepatic metastasis from colorectal cancer[J]. Thorac Cardiov Surg, 2005, 53(6): 358-364. |
|
|
|